• by bcarlson@marketresearch.com
  • July 28 2015

AACC 2015: Point-of-Care a Focus at Meeting

AACC 2015: Point-of-Care a Focus at Meeting

The American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo is attended by over 20,000 laboratory professionals and 784 exhibitors and is considered the largest IVD industry event.  This year’s meeting is being held in Atlanta, Georgia.  The story so far from Atlanta is POC.  Which is not surprising, because it may be as much as a third of the IVD market.   POC markets play in developed or developing.  They can service developed nations where physician visit can be enhanced by faster results, as well as emerging markets without healthcare infrastructure, the industry is going to stay interested. 

Point of care diagnostics, tests that take limited space and deliver results quickly, are getting a particular focus at this year’s annual gathering of clinical laboratory professionals, according to Kalorama Information.  The healthcare market researcher tracks trends at the meeting annually and notes that there’s already been a significant product launch, an approval announcement and a demonstration of a recently approved product among the point-of-care (POC) product developments at the convention.  

Kalorama estimates the world point of care market to be 17 billion as of 2014, according to its recent report detailing the POC market and profiling companies.  The report is available on its website  Point of Care Diagnostics.  (http://www.kaloramainformation.com/Point-Care-POC-9030928/ ).  Among the developments at the meeting so far:

  •  Cepheid  Cepheid announced at AACC that they will enter the point-of-care molecular diagnostics market next year with a new platform called theGeneXpert Omni.The device is battery powered and will cost less than $3,000.  Cepheid’s “Just add the patient sample and go” cartridge technology is part of this product, according to the firm.  Advanced microfluidics regulate all aspects of the testing process within the test cartridge from sample preparation and nucleic acid extraction, to amplification and detection.    
  • Alere provided demonstrations of its Alere i Influenza A & B test at its booth at the Atlanta meeting.  In January 2015, Alere i Influenza A & B became the first-ever molecular test to receive CLIA waiver, which allows for broad use by healthcare providers, ranging from hospitals and physician offices to clinics and other healthcare settings.  The test revolutionizes rapid flu testing by providing highly accurate, molecular results in less than 15 minutes.  According to the company, the isothermal nucleic acid technology amplifies at a constant temperature, removing the need for thermal cycling or sample purification steps, for much faster results.
  • bioMérieux,  announced that VIDAS® 3, its rapid low-volume analyzer, received FDA 510(k) clearance. This anlayzer can run up to 36 assays per hour and holds 27 samples.  The VIDAS 3 features enhanced automation in the pre-analytical section, improved traceability and new software capabilities, as well as a quality control program in compliance with laboratory certification standards.   The VIDAS® menu currently comprises 98 tests for the diagnosis, monitoring and prognosis of numerous pathologies. Part of this menu is dedicated to unique and high medical-value tests including, VIDAS® B•R•A•H•M•S PCT, for the measurement of procalcitonin levels, used in the early diagnosis of severe bacterial infections (such as sepsis).    Result times run from 20 to 90 minutes, depending on the test. 


Tuesday marked the first day of the AACC 2015 convention, and Kalorama expects more developments.  Kalorama staff will be walking the exhibit floor at AACC and reporting on events at the industry’s largest meeting.   The firm’s report, the World Market for Point of Care Diagnostics provides market sizing and forecasts for many POC segments.  The report can be found at: http://www.kaloramainformation.com/Point-Care-POC-9030928/